Homepage
Author:
Intellia Therapeutics, Inc.
Posted Date:
April 3, 2026
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics, Inc.
April 3, 2026
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics, Inc.
March 6, 2026
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
Intellia Therapeutics, Inc.
March 3, 2026
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
Intellia Therapeutics, Inc.
March 2, 2026
Intellia Therapeutics to Participate in Upcoming Investor Conferences
Intellia Therapeutics, Inc.
February 24, 2026
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Intellia Therapeutics, Inc.
February 19, 2026
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics, Inc.
February 8, 2026
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN
Intellia Therapeutics, Inc.
January 28, 2026
